Geode Capital Management LLC Grows Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Geode Capital Management LLC boosted its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 1.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,320,862 shares of the company’s stock after buying an additional 13,485 shares during the period. Geode Capital Management LLC’s holdings in Fulcrum Therapeutics were worth $4,716,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Barclays PLC boosted its stake in shares of Fulcrum Therapeutics by 367.1% in the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after purchasing an additional 97,565 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Fulcrum Therapeutics in the third quarter valued at $254,000. State Street Corp grew its stake in Fulcrum Therapeutics by 61.4% during the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after purchasing an additional 638,955 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Fulcrum Therapeutics during the 3rd quarter worth about $721,000. Finally, Centiva Capital LP acquired a new stake in Fulcrum Therapeutics in the 3rd quarter valued at about $273,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Leerink Partnrs downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $22.00 to $3.00 in a research note on Thursday, September 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Finally, Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Price Performance

NASDAQ FULC opened at $5.08 on Monday. The company has a 50-day moving average of $3.85 and a 200-day moving average of $5.58. Fulcrum Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $13.70. The company has a market cap of $274.01 million, a P/E ratio of -16.39 and a beta of 2.06.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.